Pages that link to "Template:Infobox publicationsection"

← Template:Infobox publicationsection

What links here

Page:  Namespace:  all (Main) Talk User User talk Wikibase.slis.ua.edu Wikibase.slis.ua.edu talk File File talk MediaWiki MediaWiki talk Template Template talk Help Help talk Category Category talk Item Item talk Property Property talk Module Module talk   Invert selection

Filters

Hide transclusions | Hide links | Hide redirects

The following pages link to Template:Infobox publicationsection:

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)

• Introduction section from DOI: 10.3390/pathogens9020148 (transclusion) ‎ (← links)
• Human Coronaviruses and the Evidence for Ocular Manifestations (Section from DOI: 10.1080/09273948.2020.1738501) (transclusion) ‎ (← links)
• Introduction (Section from DOI: 10.1080/09273948.2020.1738501) (transclusion) ‎ (← links)
• The Coronavirus Structure and Host (Section from DOI: 10.1080/09273948.2020.1738501) (transclusion) ‎ (← links)
• Feline Coronaviruses and Ocular Manifestations (Section from DOI: 10.1080/09273948.2020.1738501) (transclusion) ‎ (← links)
• Mouse Coronaviruses and Ocular Implications (Section from DOI: 10.1080/09273948.2020.1738501) (transclusion) ‎ (← links)
• Conclusion (Section from DOI: 10.1080/09273948.2020.1738501) (transclusion) ‎ (← links)
• Methods section from DOI: 10.1186/s13613-020-00653-z (transclusion) ‎ (← links)
• Results section from DOI: 10.1186/s13613-020-00653-z (transclusion) ‎ (← links)
• Discussion section from DOI: 10.1186/s13613-020-00653-z (transclusion) ‎ (← links)
• Conclusions section from DOI: 10.1186/s13613-020-00653-z (transclusion) ‎ (← links)
• Introduction section from DOI: 10.1186/s13613-020-00653-z (transclusion) ‎ (← links)
• Section 2: Protection requirements of medical personnel (from DOI: 10.1080/22221751.2020.1735265) (transclusion) ‎ (← links)
• Section 2.1: Selection of front-line personnel (from DOI: 10.1080/22221751.2020.1735265) (transclusion) ‎ (← links)
• Section 2.2: Isolation and protection requirements (from DOI: 10.1080/22221751.2020.1735265) (transclusion) ‎ (← links)
• Section 2.3: Isolation and observation of medical personnel after close contact with SARS-CoV-2 (from DOI: 10.1080/22221751.2020.1735265) (transclusion) ‎ (← links)
• Section 3: Diagnosis and treatment of SARS-CoV-2 infected patients (from DOI: 10.1080/22221751.2020.1735265) (transclusion) ‎ (← links)
• Section 3.1: Screening criteria (from DOI: 10.1080/22221751.2020.1735265) (transclusion) ‎ (← links)
• Section 3.2: Diagnostic criteria (from DOI: 10.1080/22221751.2020.1735265) (transclusion) ‎ (← links)
• Section 3.3: Examination routines of SARS-CoV-2 infected patient (from DOI: 10.1080/22221751.2020.1735265) (transclusion) ‎ (← links)
• Section 3.3.1: Screening cases on the day of visit (from DOI: 10.1080/22221751.2020.1735265) (transclusion) ‎ (← links)
• Section 3.3.2: Sequential examination of confirmed patients (from DOI: 10.1080/22221751.2020.1735265) (transclusion) ‎ (← links)
• Section 3.4: Place of treatment according to the severity of the disease (from DOI: 10.1080/22221751.2020.1735265) (transclusion) ‎ (← links)
• Section 3.4.1: Severe type (from DOI: 10.1080/22221751.2020.1735265) (transclusion) ‎ (← links)
• Section 3.4.2: Critically ill type (from DOI: 10.1080/22221751.2020.1735265) (transclusion) ‎ (← links)
• Section 3.5: Treatment (from DOI: 10.1080/22221751.2020.1735265) (transclusion) ‎ (← links)
• Section 3.5.1: General treatment (from DOI: 10.1080/22221751.2020.1735265) (transclusion) ‎ (← links)
• Section 3.5.2: Oxygen therapy (from DOI: 10.1080/22221751.2020.1735265) (transclusion) ‎ (← links)
• Section 3.5.2.1: Choice of oxygen therapy (from DOI: 10.1080/22221751.2020.1735265) (transclusion) ‎ (← links)
• Section 3.5.2.2: The way of respiratory support (from DOI: 10.1080/22221751.2020.1735265) (transclusion) ‎ (← links)
• Section 3.5.3: Antiviral treatment (from DOI: 10.1080/22221751.2020.1735265) (transclusion) ‎ (← links)
• Section 3.5.4: Glucocorticoid therapy (from DOI: 10.1080/22221751.2020.1735265) (transclusion) ‎ (← links)
• Section 3.5.5: Intravenous immunoglobulin (from DOI: 10.1080/22221751.2020.1735265) (transclusion) ‎ (← links)
• Section 3.5.6: Empirical antimicrobial therapy (from DOI: 10.1080/22221751.2020.1735265) (transclusion) ‎ (← links)
• Section 4: Protection and transfer (from DOI: 10.1080/22221751.2020.1735265) (transclusion) ‎ (← links)
• Section 5: Criteria of isolation release and discharge (from DOI: 10.1080/22221751.2020.1735265) (transclusion) ‎ (← links)
• Disclosure statement (from DOI: 10.1080/22221751.2020.1735265) (transclusion) ‎ (← links)
• Section 1: Introduction (from DOI: 10.1080/22221751.2020.1735265) (transclusion) ‎ (← links)
• Section 3.2.7PI3K/AKT/mTOR signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5) (transclusion) ‎ (← links)
• Section 2: The concept of CSCs (from DOI: 10.1038/s41392-020-0110-5) (transclusion) ‎ (← links)
• Section 2.1: Biological characteristics of CSCs (from DOI: 10.1038/s41392-020-0110-5) (transclusion) ‎ (← links)
• Section 2.2: Isolation and identification of CSCs (from DOI: 10.1038/s41392-020-0110-5) (transclusion) ‎ (← links)
• Section 3: Factors regulating CSCs (from DOI: 10.1038/s41392-020-0110-5) (transclusion) ‎ (← links)
• Section 3.1: Major transcription factors in CSCs (from DOI: 10.1038/s41392-020-0110-5) (transclusion) ‎ (← links)
• Section 3.2: Major signaling pathways in CSCs (from DOI: 10.1038/s41392-020-0110-5) (transclusion) ‎ (← links)
• Section 3.2.1: Wnt signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5) (transclusion) ‎ (← links)
• Section 3.2.2: Notch signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5) (transclusion) ‎ (← links)
• Section 3.2.3: Hh signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5) (transclusion) ‎ (← links)
• Section 3.2.4: NF-kappaB signaling pathway in CSCs (from DOI: 10.1038/s41392-020-0110-5) (transclusion) ‎ (← links)
• Section 3.2.5: JAK-STAT signaling pathway (from DOI: 10.1038/s41392-020-0110-5) (transclusion) ‎ (← links)

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)